HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy
- Helena A. Yu
- , Yasushi Goto
- , Hidetoshi Hayashi
- , Enriqueta Felip
- , James Chih Hsin Yang
- , Martin Reck
- , Kiyotaka Yoh
- , Se Hoon Lee
- , Luis Paz-Ares
- , Benjamin Besse
- , Paolo Bironzo
- , Dong Wan Kim
- , Melissa L. Johnson
- , Yi Long Wu
- , Thomas John
- , Steven Kao
- , Toshiyuki Kozuki
- , Erminia Massarelli
- , Jyoti Patel
- , Egbert Smit
- Memorial Sloan-Kettering Cancer Center
- National Cancer Center Japan
- Kindai University
- Vall d'Hebron Institute of Oncology
- National Taiwan University
- German Center of Lung Research
- Hospital Universitario 12 de Octubre
- Gustave Roussy
- University of Turin
- Seoul National University
- Sarah Cannon Research Institute
- Guangdong Academy of Medical Sciences
- University of Melbourne
- Chris O'Brien Lifehouse
- National Hospital Organization Shikoku Cancer Center
- City of Hope National Med Center
- Northwestern University
- Antoni van Leeuwenhoek Hospital
- Cedars-Sinai Medical Center
- Daiichi Sankyo Company, Limited
- Dana-Farber Cancer Institute
Research output: Contribution to journal › Article › peer-review
226
Link opens in a new tab
Scopus
citations